NASDAQ:AKYA Akoya Biosciences Q1 2025 Earnings Report $1.23 -0.03 (-2.38%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$1.26 +0.03 (+2.44%) As of 04:38 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Akoya Biosciences EPS ResultsActual EPS-$0.32Consensus EPS -$0.29Beat/MissMissed by -$0.03One Year Ago EPSN/AAkoya Biosciences Revenue ResultsActual Revenue$16.64 millionExpected Revenue$20.19 millionBeat/MissMissed by -$3.55 millionYoY Revenue GrowthN/AAkoya Biosciences Announcement DetailsQuarterQ1 2025Date5/12/2025TimeBefore Market OpensConference Call DateMonday, May 12, 2025Conference Call Time12:00AM ETUpcoming EarningsAkoya Biosciences' Q2 2025 earnings is scheduled for Monday, August 4, 2025Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Akoya Biosciences Earnings HeadlinesKent Lake Responds to Quanterix's Post-Effective Amendment and Akoya's Superior $1.40-per-Share Alternative ProposalMay 23, 2025 | prnewswire.comAkoya surges as unsolicited buyout offer risks Quanterix mergerMay 21, 2025 | msn.com[Wanted] 250 intrepid soulsHe Called this 106X Opportunity Before Reddit… and Before Elon Musk Before GameStop rocketed up to 10,633, Jonathan Rose saw something strange: A sudden surge in options volume — thousands of contracts flooding in. The money hit deep inside the CBOE before Reddit posts created the short squeeze and before Elon's tweet sent GameStop flying. Jonathan calls it the "Big-Money Tell," and it's flagged dozens of big trade opportunities including: 462.5% in C3.ai, 245.13% in Criteo, and 39.46% in Roku. And these are just some of the gains the "tell" has identified. Even better: He says the next big set-up could be forming right now. And there's still time for you to get in before it kicks off as soon as seven days from now.June 16, 2025 | Masters in Trading (Ad)Akoya Biosciences Reports First Quarter 2025 Financial ResultsMay 12, 2025 | globenewswire.comAKOYA BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akoya Biosciences, Inc. - AKYAMay 7, 2025 | businesswire.comAkoya Unveils ADC Breast Cancer Assay, Validates IO60 Spatial Panel At AACR 2025April 26, 2025 | nasdaq.comSee More Akoya Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Akoya Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Akoya Biosciences and other key companies, straight to your email. Email Address About Akoya BiosciencesAkoya Biosciences (NASDAQ:AKYA), a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. It has a collaboration agreement with NeraCare that enables personalized therapy selection for early-stage melanoma patients. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.View Akoya Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Broadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s NextBroadcom Earnings Preview: AVGO Stock Near Record HighsUlta’s Beautiful Q1 Earnings Report Points to More Gains Aheade.l.f. Beauty Sees Record Surge After Earnings, Rhode Deal Upcoming Earnings Accenture (6/20/2025)FedEx (6/24/2025)Micron Technology (6/25/2025)Paychex (6/25/2025)NIKE (6/26/2025)Bank of America (7/14/2025)Wells Fargo & Company (7/14/2025)JPMorgan Chase & Co. (7/14/2025)Interactive Brokers Group (7/15/2025)América Móvil (7/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
